Coombes R Charles, Caballero Otavia L, Shousha Sami, Ghaem-Maghami Sadaf, Woodley-Barker Laura, Wilhelm-Benartzi Charlotte S, Neville A Munro
Imperial College Healthcare NHS Trust & Imperial College, London, Hammersmith Hospital, London, UK.
Ludwig Collaborative Laboratory, Ludwig Institute for Cancer Research, Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Oncoscience. 2017 Apr 28;4(3-4):33-40. doi: 10.18632/oncoscience.348. eCollection 2017 Mar.
At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC.
14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033).
We identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2.
Expression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.
目前，很难预测哪些导管原位癌（DCIS）患者随后会发展为浸润性乳腺癌（IDC）。我们团队最近的一项调查显示，NY-ESO-1和MAGEA在DCIS中均有表达。本研究旨在确定这些抗原的表达是否与IDC的后期发展有关。
42例患者中有14例（33%）在随访期间发展为浸润性乳腺癌。在复发的DCIS病例中，只有1例在诊断时NYESO-1呈阳性。相比之下，在28例无疾病复发的患者中，有15例（54%）的DCIS样本表达NY-ESO-1。（排列卡方检验p = 0.0033）。
我们确定了42例DCIS患者，并对他们进行了超过10年的随访。通过免疫染色检测NY-ESO-1和MAGEA，同时在所有切片上检测CD8 +浸润情况以及传统标志物雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）。
NY-ESO-1的表达可能预测哪些患者随后不会发展为浸润性乳腺癌，因此可能有助于确定DCIS患者的预后。
